Zhitong Finance App News, Ruibo Bio-B (06938.HK) issued an announcement. The company has submitted a Phase I clinical trial application (CTA) in the European Union for the dual-target siRNA drug SR122 (a type of GalNAC-conjugated siRNA therapy for the treatment of dyslipidemia including severe hypertriglyceridemia (SHTG) and mixed dyslipidemia).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.